We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: weatherproof who wrote (45930)4/27/2018 11:38:36 PM
From: drtom1234  Read Replies (1) | Respond to of 58497
I agree that RR based on available information is likely to be quite good. I don't think the trial was stopped for efficacy either, I just wonder if they have accrued enough patients in those indications to satisfy FDA requirements for AA. Starting studies up is expensive, and I'm not sure why they would need or want to spend that money on two new P2 studies(urothelial and ER+ breast), when they could satisfactorily accrue those patients under the umbrella of the pre-existing basket trial, just as they did with the TNBC indication.